Corcept to present Phase 3 ROSELLA Lifyorli ovarian cancer survival subgroup data at ASCO 2026

• Corcept scheduled new subgroup analyses from pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) with nab-paclitaxel in platinum-resistant ovarian cancer for oral presentation at ASCO on May 29, 2026.
• Presentation will focus on how prior taxane use relates to overall survival outcomes in patients receiving combination therapy versus nab-paclitaxel alone, without disclosing new efficacy figures in announcement.
• Lifyorli gained FDA clearance in March 2026 for use with nab-paclitaxel in adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1-3 systemic regimens, including bevacizumab.
• Corcept positioned Lifyorli as first FDA-cleared selective glucocorticoid receptor antagonist, with NCCN listing as preferred regimen supporting near-term commercial uptake.
• Company also disclosed it filed a Marketing Authorisation Application in Europe, signaling push to expand access beyond US market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260421589301) on April 21, 2026, and is solely responsible for the information contained therein.